Oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction

Area of Science:

• Cardiovascular Science
• Metabolic Disease Research
• Pharmacology

Background:

• Diabetes and hyperglycemia increase cardiovascular disease risk.
• Oxidative stress, apoptosis, hexosamine biosynthetic pathway (HBP), and ubiquitin-proteasome system (UPS) dysfunction contribute to hyperglycemia-induced cardiac damage.
• Oleanolic acid (OA), a natural compound, exhibits antioxidant properties.

Purpose of the Study:

• To investigate the potential of oleanolic acid (OA) in mitigating hyperglycemia-mediated cardiac pathophysiology.
• To assess OA's effects on oxidative stress, apoptosis, HBP flux, and UPS activity in cardiac cells and tissues.
• To evaluate OA's cardioprotective effects against ischemia-reperfusion injury under hyperglycemic conditions.

Main Methods:

• Experiments utilized H9c2 cardiac myoblasts exposed to high glucose, isolated rat hearts subjected to ischemia-reperfusion, and in vivo models of streptozotocin-induced diabetes in rats.
• Oleanolic acid (OA) was administered at varying doses and durations in different experimental setups.
• Cardiac function, oxidative stress markers, apoptosis, HBP flux, and proteasomal activity were assessed.

Main Results:

• OA treatment effectively reduced high glucose-induced oxidative stress and apoptosis in cardiac myoblasts.
• OA demonstrated significant cardioprotection in ex vivo and in vivo models of ischemia-reperfusion under hyperglycemic conditions.
• OA administration led to decreased oxidative stress, apoptosis, HBP flux, and proteasomal activity following ischemia-reperfusion.
• Long-term OA treatment improved cardiac function in streptozotocin-diabetic rats.

Conclusions:

• Oleanolic acid (OA) effectively attenuates hyperglycemia-induced cardiac cell damage and dysfunction.
• OA exhibits promising cardioprotective effects against ischemia-reperfusion injury, particularly in hyperglycemic states.
• OA represents a potential therapeutic agent for managing cardiovascular complications associated with acute hyperglycemia and diabetes.